ONKOLOGIE / Onkologie. 2023;17(4):267-272 / www.onkologiecs.cz 272 PŘEHLEDOVÉ ČLÁNKY KONSOLIDAČNÍ LÉČBA BRENTUXIMAB VEDOTINEM U PACIENTŮ S RELABUJÍCÍM/REFRAKTERNÍM KLASICKÝM HODGKINOVÝM LYMFOMEM PO PROVEDENÍ AUTOLOGNÍ TRANSPLANTACE HEMATOPOETICKÝCH KMENOVÝCH BUNĚK V ČESKÉ REPUBLICE s relapsem/progresí klasického Hodgkinova lymfomu na principu eradikace zbytkové nemoci. Po letech zkušeností z reálné klinické praxe můžeme konstatovat, že tato indikace brentuximabu naplňuje svůj potenciál a významně zlepšuje vyhlídky pacientů po ASCT na dosažení trvalé remise za cenu přijatelné a obvykle dobře řešitelné toxicity. MH CZ – DRO (FNOl, 00098892) AZV NU22-03-00182 from Ministry of Health of the Czech Rep. and research project Cooperatio which are awarded by the Charles University in Prague. LITERATURA 1. Brice P, DeKerviler E, Friedberg JW. Classical Hodgkin lymphoma. Lancet. 2021;398:1518-1527. 2. Samara Y, Mei M. Autologous Stem Cell Transplantation in Hodgkin Lymphoma – Latest Advances in the Era of Novel Therapies. Cancers. 2022;14:1738. 3. SPC Adcetris. Available from: www.sukl.cz. [online] [cited: 24.03.2023]. 4. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem- -cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853-1862. 5. Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639-2642. 6. Akay OM, Ozbalak M, Pehlivan M, et al. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study. Hematol Oncol. 2021;39(4):498-505. 7. Massaro F, Pavone V, Stefani PM, et al. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. Hematol Oncol. 2022;40(1):31-39. 8. Marouf A, Cottereau AS, Fouquet G, et al. Outcomes of refractory or relapsed Hodgkin lymphoma patients with post autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study. Haematologica. 2022;107(7):1681-1686. 9. Martinez C, de Haro ME, Romero S, et al. Impact of pre‑ and/or post‑autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high‑risk Hodgkin lymphoma. Ann Hematol. 2023;102:429-437. 10. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068. 11. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. 12. Younes A, Gopal AK, Smith SE, et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin‘s Lymphoma. J Clin Oncol. 2012;30(18):2183-2189. 13. Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562-1566. 14. Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2018;390:2790-2802. 15. Driessen J, Tonino SH, Moskowitz AJ, et al. How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents. Hematology Am Soc Hematol Educ Program. 2021(1):240-246. PIŠTE JAKO PROFESIONÁL Zkontrolujte si, jestli ve svých prezentacích, článcích atd. neděláte zbytečné chyby Ty nejtypičtější jsme pro vás sepsali a vysvětlili na sociálních sítích a našem webu. ➜ ➜
RkJQdWJsaXNoZXIy NDA4Mjc=